Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §112 only | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MALEVIC, DJURA | 1 | 78.1% | +10.3% |
| LU, CHENG | 1 | 54.1% | +67.9% |
| GAMETT, DANIEL C | 1 | 67.6% | +28.8% |
| PARKIN, JEFFREY S | 1 | 63.5% | +21.4% |
| SCHULTZHAUS, JANNA NICOLE | 1 | 33.3% | +40.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253981 | BROADLY NEUTRALIZING ANTIBODIES TO TICK-BORNE ENCEPHALITIS AND RELATED VIRUSES | GAMETT, DANIEL C | 66d overdue |
| 17995401 | PHAGE-ENCODED AcrVIA1 FOR USE AS AN INHIBITOR OF THE RNA-TARGETING CRISPR-Cas13 SYSTEMS | PARKIN, JEFFREY S | 28d overdue |
| 18255043 | COMPOSITIONS AND METHODS FOR RAPID PRODUCTION OF VERSATILE SINGLE DOMAIN ANTIBODY REPERTOIRES | LU, CHENG | 17d overdue |
| 16965292 | Methods for Analyzing Genetic Data to Classify Multifactorial Traits Including Complex Medical Disorders | SCHULTZHAUS, JANNA NICOLE | 6d |
| 18557187 | Spatiotemporal Multiplexing Module | MALEVIC, DJURA | 15d |
| Art Unit | Apps |
|---|---|
| 2884 | 1 |
| 1642 | 1 |
| 1647 | 1 |
| 1671 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557187 | Spatiotemporal Multiplexing Module | MALEVIC, DJURA | 2884 | §103 | Final Rejection | 15d | Pending | Oct 25, 2023 |
| 18255043 | COMPOSITIONS AND METHODS FOR RAPID PRODUCTION OF VERSATILE SINGLE DOMAIN ANTIBODY REPERTOIRES | LU, CHENG | 1642 | §103 | Non-Final OA | 17d overdue | Pending | May 30, 2023 |
| 18253981 | BROADLY NEUTRALIZING ANTIBODIES TO TICK-BORNE ENCEPHALITIS AND RELATED VIRUSES | GAMETT, DANIEL C | 1647 | §112 | Non-Final OA | 66d overdue | Pending | May 23, 2023 |
| 17995401 | PHAGE-ENCODED AcrVIA1 FOR USE AS AN INHIBITOR OF THE RNA-TARGETING CRISPR-Cas13 SYSTEMS | PARKIN, JEFFREY S | 1671 | §112 | Non-Final OA | 28d overdue | Pending | Oct 03, 2022 |
| 16965292 | Methods for Analyzing Genetic Data to Classify Multifactorial Traits Including Complex Medical Disorders | SCHULTZHAUS, JANNA NICOLE | 1685 | §112 | Final Rejection | 6d | Pending | Jul 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial